|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2003-8-27
|
|
pubmed:abstractText |
The current study was performed to determine the maximum tolerated dose (MTD), toxicity, and outcome of infusional 5 bromo-2'-deoxyuridine (bromodeoxyuridine; BUdR) given with accelerated fractionation whole brain radiation therapy (WBRT) after chemotherapy for the treatment of primary central nervous system lymphoma (PCNSL).
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
pubmed-author:CabanillasFernandoF,
pubmed-author:CoxJames DJD,
pubmed-author:DabajaBouthaina SBS,
pubmed-author:HaChul SCS,
pubmed-author:KyritsisAthanassios PAP,
pubmed-author:LevinVictorV,
pubmed-author:McLaughlinPeterP,
pubmed-author:MeyersChristina ACA,
pubmed-author:PretiH AlejandroHA,
pubmed-author:ProBarbaraB,
pubmed-author:SeabrookeLee FLF,
pubmed-author:WilderRichard BRB,
pubmed-author:YungW K AlfredWK
|
|
pubmed:copyrightInfo |
Copyright 2003 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
98
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1021-8
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:12942571-Adult,
pubmed-meshheading:12942571-Aged,
pubmed-meshheading:12942571-Antimetabolites, Antineoplastic,
pubmed-meshheading:12942571-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12942571-Brain Diseases,
pubmed-meshheading:12942571-Bromodeoxyuridine,
pubmed-meshheading:12942571-Central Nervous System Neoplasms,
pubmed-meshheading:12942571-Cisplatin,
pubmed-meshheading:12942571-Combined Modality Therapy,
pubmed-meshheading:12942571-Cranial Irradiation,
pubmed-meshheading:12942571-Cytarabine,
pubmed-meshheading:12942571-Dexamethasone,
pubmed-meshheading:12942571-Dose-Response Relationship, Drug,
pubmed-meshheading:12942571-Female,
pubmed-meshheading:12942571-Humans,
pubmed-meshheading:12942571-Idarubicin,
pubmed-meshheading:12942571-Infusions, Intravenous,
pubmed-meshheading:12942571-Lymphoma,
pubmed-meshheading:12942571-Male,
pubmed-meshheading:12942571-Methotrexate,
pubmed-meshheading:12942571-Middle Aged,
pubmed-meshheading:12942571-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
|
|
pubmed:affiliation |
Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Clinical Trial, Phase I
|
